FRAMINGHAM, Mass., Sept. 17, 2012 /PRNewswire/ -- Dune Medical Devices announced today results of a study published in the journal Nature.com demonstrating the utility of the MarginProbe technology in prostate cancer surgery. The prototype device, developed by Dune Medical, was designed to enable use of Dune's patented radiofrequency spectroscopy technology in radical prostatectomy procedures, to aid surgeons in complete removal of the prostate gland while achieving negative surgical margins. The study reports results of over 15,000 measurements in 49 patients, which showed the ability to discriminate between cancer and healthy tissue with a very high degree of accuracy.
"The ability to differentiate between cancer and healthy tissue during radical prostatectomy is crucial to successful prostate cancer surgery," said Dr. Zohar Dotan, head of uro-oncology service at Sheba Medical Center in Tel Hashomer, Israel. "Positive margins after radical prostatectomy are common, and increase the probability of biochemical failure and salvage radiotherapy following surgery. Existing techniques to help the surgeon intraoperatively are inadequate. The ability of a device like the Dune Medical device would be a significant help to surgeons and patients."
"The ability to detect prostate cancer margins with a high degree of accuracy represents significant opportunity to improve the standard of care in prostate cancer surgery," said Dune's President & Chief Technology Officer, Dr. Dan Hashimshony. "This represents another application of MarginProbe technology and just as our MarginProbe System represents a powerful tool in surgeons' fight against breast cancer, we believe these data show similar opportunity in prostate cancer surgery. We believe that the technology platform upon which both products were developed represents substantial opportunity for multiple surgical oncology applications."
About Dune Medical Devices
Dune Medical Devices was founded in 2002 by Dr. Dan Hashimshony to realize the extraordinary medical potential of its proprietary tissue characterization technology. Offering surgeons and radiologists the real time ability to identify cancerous tissues and react immediately, this technology holds the promise for a broad range of surgical and diagnostic applications. The MarginProbe System is Dune's first commercial product and is commercially available in Europe. The MarginProbe device is an investigational device that is not yet available for sale in the U.S.
Dune Medical Devices is a privately held company financed by Apax Partners since 2004. It has offices in the U.S., Israel, and Switzerland. For more information, please visit www.dunemedical.com
Contact: Michael Graffeo, Director of Marketing, Dune Medical Devices
508-620-2782 / email@example.com
SOURCE Dune Medical Devices